Evidence map›Paper›PMID 33912752›Full record

ArticleKidney international reports2021

Biomarkers, Clinical Features, and Rechallenge for Immune Checkpoint Inhibitor Renal Immune-Related Adverse Events.

Busra Isik, Mariam P Alexander, Sandhya Manohar, Lisa Vaughan, Lisa Kottschade, Svetomir Markovic, John Lieske, Aleksandra Kukla, Nelson Leung, Sandra M Herrmann

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 5 pooled it
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 5 syntheses or guidelines pooled it, 105 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact.Journal of immunotherapy and precision oncology · 2026
    Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Practice patterns and outcomes in cancer patients developing immune checkpoint inhibitors-related AKI.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026
    Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Ten tips for an onco-nephrology clinic.Clinical kidney journal · 2025
    Review

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Busra IsikDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
Mariam P AlexanderDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Sandhya ManoharDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
Lisa VaughanDepartment of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
Lisa KottschadeDepartment of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Svetomir MarkovicDepartment of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.
John LieskeDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
Aleksandra KuklaDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
Nelson LeungDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
Sandra M HerrmannDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
Mayo Clinic · USMayo Clinic in Florida · US

Funding

Hypoxic preconditioning for the improvement of the regenerative capacity of adipose-derived mesenchymal stem cells and its application in chronic kidney disease due to hypertensive nephropathyK08DK118120 · NIDDK · MAYO CLINIC ROCHESTER · PI HERRMANN, SANDRA M · 2018 to 2022
$800k
NIDDK NIH HHS K08 DK118120
6 · The paper itself

Abstract

introductionImmune checkpoint inhibitors (ICIs) are effective in treating several cancers; however, acute kidney injury (AKI) can occur as part as an immune-related adverse event (iRAE). Biomarkers at the time of AKI diagnosis may help determine whether they are ICI- related and guide therapeutic strategies.

methodsIn this retrospective study, we reviewed patients with cancer treated with ICI therapy between 2014 and 2020 who developed AKI (defined as a ≥1.5-fold increase in serum creatinine [SCr]) that was attributed to ICI (ICI-AKI) and compared them with an adjudicated non-ICI-AKI group. Clinical and laboratory features, including SCr, serum C-reactive protein (CRP), and urine retinol binding protein/urine creatinine (uRBP/Cr) levels at AKI event were evaluated.

resultsThere were 37 patients with ICI-AKI and 13 non-ICI-AKI referents in the cohort for analysis. At time of AKI, SCr, CRP, and uRBP/Cr were significantly higher in the ICI-AKI compared with the non-ICI-AKI patients (median [interquartile range (IQR)] SCr 2.0 [1.7, 2.9] vs. 1.5 [1.3, 1.6] mg/dl, serum CRP 54.0 [33.7, 90.0] vs. 3.5 [3.0, 7.9] mg/l, and uRBP/Cr 1927 [1174, 46,522] vs. 233 [127, 989] μg/g Cr, respectively,

conclusionOur findings suggest that serum CRP and uRBP/Cr may help to differentiate AKI due to ICI from other causes.

Indexed as

acute kidney injurybiomarkersimmune checkpoint inhibitorsimmune checkpoint-rechatllengeimmune-related adverse eventinterstitial nephritis

Identifiers

PMID33912752
PMCPMC8071627
OpenAlexW3127826897

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.